Cellectar Biosciences
NASDAQ: CLRBMadison, US · Delaware corporation · 1 known investors
Cellectar Biosciences is a clinical-stage oncology company developing targeted cancer therapies using its proprietary PLE (phospholipid ether) delivery platform, which delivers therapeutic payloads directly to cancer cells. It focuses on advanced cancers with high unmet needs, including work related to triple-negative breast cancer.
BiotechHealthtech
Founders & leadership
JE
John E. Friend IIExecutive
JV
James V. CarusoExecutive
JL
Jarrod LongcorExecutive
SL
Stefan LorenNamed on SEC filing
JP
John P. HamillNamed on SEC filing
JP
Jamey P. WeichertNamed on SEC filing
PB
Paul BernsNamed on SEC filing
SP
Simon PedderNamed on SEC filing
CJ
Chad J. KoleanNamed on SEC filing
Board
JN
John NeisBoard director
FW
Frederick W. DriscollBoard director
DJ
Douglas J. SwirskyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$58.4M disclosed across 5 rounds · 2014–2023
▶$24.5MraisedSep 2023 · 21 investors · BiotechnologyRule 506(b)
▶$24.5MraisedSep 2023 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chad J. KoleanExecutive Officer
- Jarrod LongcorExecutive Officer
- Darrell Shane LeaExecutive Officer
- Frederick W. DriscollDirector
- James V. CarusoExecutive Officer, Director
- Stefan D. LorenDirector
- John NeisDirector
- Asher Alban Chanan-KahnDirector
- Douglas J. SwirskyDirector
- Andrei ShustovExecutive Officer
- Offering amount
- $24.5M
- Amount sold
- $24.5M
- Minimum investment
- $84.4K
- Sales commissions
- $1.4M
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.5MraisedJan 2021 · 16 investors · PharmaceuticalsRule 506(b)
▶$20.5MraisedJan 2021 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dov ElefantExecutive Officer
- James V. CarusoExecutive Officer, Director
- Frederick W DriscollDirector
- Stephen A. HillDirector
- John FriendDirector
- John NeisDirector
- Douglas J. SwirskyDirector
- Jarrod LongcorExecutive Officer
- Stefan LorenDirector
- Offering amount
- $20.5M
- Amount sold
- $20.5M
- Sales commissions
- $1.4M
- Placement agents
- Oppenheimer & Co. Inc
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMay 2019 · 11 investors · PharmaceuticalsRule 506(b)
▶$5MraisedMay 2019 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James V. CarusoExecutive Officer, Director
- Stephen A. HillDirector
- Jarrod LongcorExecutive Officer
- Douglas J. SwirskyDirector
- Frederick W DriscollDirector
- Charles T. BernhardtExecutive Officer
- John NeisDirector
- Stefan LorenDirector
- Offering amount
- $14.6M
- Amount sold
- $5M
- Sales commissions
- $378.4K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedOct 2017 · 3 investors · PharmaceuticalsRule 506(b)
▶$7.8MraisedOct 2017 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frederick W. DriscollDirector
- John E. Friend IIExecutive Officer
- Douglas J. SwirskyDirector
- Stefan LorenDirector
- Stephen A. HillDirector
- James V. CarusoExecutive Officer, Director
- Jarrod LongcorExecutive Officer
- John P. HamillExecutive Officer
- John NeisDirector
- Offering amount
- $7.8M
- Amount sold
- $7.8M
- Sales commissions
- $582.5K
- Placement agents
- Landenburg Thalmann & Co. Inc.
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$617.5KraisedAug 2014 · 8 investors · PharmaceuticalsRule 506(b)
▶$617.5KraisedAug 2014 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen A. HillDirector
- Jamey P. WeichertExecutive Officer, Director
- Paul BernsDirector
- Simon PedderExecutive Officer, Director
- Chad J. KoleanExecutive Officer
- John NeisDirector
- Offering amount
- $1M
- Amount sold
- $617.5K
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Robinhood28 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha27 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Companies competing with Cellectar Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2007 | $150.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Cellectar Biosciences do?
- Cellectar Biosciences is a clinical-stage oncology company developing targeted cancer therapies using its proprietary PLE (phospholipid ether) delivery platform, which delivers therapeutic payloads directly to cancer cells. It focuses on advanced cancers with high unmet needs, including work related to triple-negative breast cancer.
- Who are Cellectar Biosciences's investors?
- Cellectar Biosciences's investors include Venture Investors Health Limited Partnership.
- How much funding has Cellectar Biosciences raised?
- Cellectar Biosciences has disclosed $58.4M raised across 5 rounds.
- Where is Cellectar Biosciences headquartered?
- Cellectar Biosciences is headquartered in Madison, US.